 SOUTH SAN FRANCISCO, Calif., March 25, 2021 GLOBE NEWSWIRE -- Nkarta, Inc. Nasdaq: NKTX, a clinical-stage biopharmaceutical company developing engineered natural killer NK cell therapies to treat cancer, today reported financial results for the fourth quarter and year ended December 31, 2020. 